Cincinnati Children’s researchers collaborate with colleagues in Uganda and beyond to help children where the disease burden is highest. New findings published in NEJM.
Fewer serious complications. Fewer hospitalizations and blood transfusions. Better growth and development. And a markedly lower risk of death from the complications of sickle cell anemia.
These are the benefits documented from 10 years of continuous hydroxyurea treatment provided in the NOHARM trial to a group of young children in Uganda, which has one of the world’s largest number of people living with the painful disorder known for causing sickle-shaped red blood cells. These improved outcomes were highlighted May 27, 2026, in a report published by The New England Journal of Medicine.